CALIWAY BIOPHARMACEUTICALS CO., LTD.

Altre lingue Caliway Biopharmaceuticals Co., Ltd.

Azioni

6919

TW0006919004

Prezzo di chiusura Taipei Exchange Altri mercati azionari 00:00:00 07/06/2024			Variaz. 5gg	Var. 1 gen.
450 ^TWD	+4,29%		+8,04%	+135,29%

13/05	Caliway Biopharmaceuticals Co., Ltd. riporta i risultati degli utili per il primo trimestre conclusosi il 31 marzo 2024	CI
25/04	Caliway Biopharmaceuticals Co., Ltd. annuncia che lo studio di Fase 2 CBL-514 per il trattamento della cellulite ha soddisfatto tutti gli endpoint primari e secondari	CI

Altre lingue

Sblocca tutte le notizie: sii il primo a essere informato e reagisci prima dei mercati!

Registrazione 100% gratuita

Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05
Caliway Biopharmaceuticals Co., Ltd. Announces CBL-514 Phase 2 Study for Cellulite Treatment Met All Primary and Secondary Endpoints	25/04
Caliway Biopharmaceuticals Gets ODD from US FDA to Cure Dercum's Disease	05/03
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04/03
Caliway Biopharmaceuticals Receives U.S. FDA Fast Track Designation for CBL-514 for the Treatment of Dercum's Disease	15/02
Caliway Biopharmaceuticals Gets Australian Bellberry HREC Nod to Study Fat Reduction Drug	24/01
Caliway Biopharmaceuticals Receives First Approval of CBL-514 Pivotal Phase 3 Study Application for Subcutaneous Fat Reduction	23/01
Caliway Biopharmaceuticals Gets US FDA Nod for Phase 2 Trial of Dercum's Disease Drug	09/01
Caliway Biopharmaceuticals Announces FDA Acceptance of CBL-514 IND Application for Placebo-Controlled Phase 2 Study to Treat Dercum's Disease	08/01
Caliway Biopharmaceuticals Co., Ltd. announced that it has received $100 million in funding	16/12
Caliway's CBL-514 Achieves Better Efficacy Than Liposuction, Reducing over 300Ml of Subcutaneous Fat on Average in CBL-0202 Study	02/10/23
Caliway Biopharmaceuticals Completes Recruitment for Severe Cellulite Drug Study	20/09/23
Caliway Biopharmaceuticals Announces CBL-514 Phase 2 Study Topline Results for Dercum's Disease, Showing 64.5% of Lipomas with Complete Clearance or Dimensions Reduction of over 50% and Reduced Pain by 4.7	13/09/23
Caliway Biopharmaceuticals Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	11/08/23
Caliway Biopharmaceuticals Announces Positive Data from CBL-0201EFP Phase 2-Stage 1 Study of CBL-514 in Treating Moderate to Severe Cellulite	28/06/23
Caliway Biopharmaceuticals Co., Ltd.(TPEX:6919) added to S&P Global BMI Index	19/06/23
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2B Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction	31/05/23
Caliway Biopharmaceuticals Announces Initiation of Subject Recruitment in CBL-0204 Phase 2b Study Evaluating the Efficacy of CBL-514 in Abdominal Subcutaneous Fat Reduction	31/05/23

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Borsa valori
Azioni
Azione 6919
Notizie Caliway Biopharmaceuticals Co., Ltd.
Altre lingue

Tutti i resoconti di oltre 9.000 società, il giorno stesso della pubblicazione!

fermer